Delivery Order SPE2DB25D3108-SPE2DB25FPDSY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,848.75 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single transaction under the company's larger pharmaceutical supply framework with the federal...
- The Defense Logistics Agency awarded a delivery order valued at $10,186.58 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This firm fixed price, non-set-aside delivery order was issued on August 27, 2025, with an ultimate completion date of August 28, 2025. The products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $2,724.55 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government...
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $14,343.19 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $10,285.92 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This is a firm fixed price, competitively awarded contract with a completion date of August 15, 2025, and performance to be executed at the contractor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract issued under AmerisourceBergen's broader relationship with the Defense...
- The Defense Logistics Agency awarded a $15,944.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,356.64 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This firm fixed price delivery order, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive, non-set-aside award. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $5,144.31. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside, competitively awarded procurement. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDSYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,546.91 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 25, 2025, with completion scheduled for August 26, 2025. This firm fixed-price, non-set-aside delivery order was awarded competitively and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply chain requirements for military and related healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive federal contract portfolio with DLA and has demonstrated its capability to fulfill competitive procurement requirements across multiple therapeutic domains, ranging from small-value transactions to substantial orders exceeding $45,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 8/25/25 |